$16.10
+2.7%Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Weak cash conversion. Significant portion of earnings not converting to cashโreview working capital trends and capital intensity.
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโmonitor closely.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
IART โข NASDAQ
| Integra LifeSciences Holdings Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-516.5M | -6.9M | 67.7M | 180.6M | 169.1M | 133.9M | 50.2M | 60.8M | 64.7M | 74.6M | 6.9M | 34M | -17M | 41.2M | 28M | 65.7M | 51M | 34.9M | 33.5M | 29.4M | |
0.0 | 140.9M | 123.5M | 118.3M | 119.8M | 116M | 109.5M | 110.7M | 88.9M | 72.7M | 58.9M | 61.1M | 47M | 52.6M | 50.2M | 39.2M | 39.7M | 33.1M | 27M | 21.5M | |
0.0 | -20.7M | -11.9M | -4.6M | -2.8M | -64.1M | -19M | -8.2M | -67.3M | -6.5M | -351K | -964K | -10.8M | 1.5M | 1.2M | 4.1M | 548K | -28.3M | -12.7M | 3.2M | |
0.0 | 24.4M | 20.1M | 27.7M | 36.2M | 19.6M | 21.3M | 20.8M | 21.6M | 17.3M | 15.5M | 15.1M | 10.4M | 9.1M | 26.8M | 17.2M | 15.6M | -1.2M | -1.2M | -1.3M | |
600.6M | 22.8M | 22M | -18.1M | -28.1M | 39.8M | 226.3M | 13.8M | 7.9M | -30.4M | 30.6M | 9.5M | 57.5M | -21.7M | 13.3M | -1.6M | 6.7M | 57.5M | 20.7M | 21.1M | |
(0.0) | (22.7M) | (23.6M) | (35.9M) | (49.5M) | (29.8K) | (16.2K) | (10.4K) | (14.6K) | (4.3K) | (21.3K) | (6.8K) | (3.7K) | (12.7K) | (14.5K) | (0.0) | (20.5M) | (41.2M) | (0.0) | (0.0) | |
-33.7M | -31M | -81.6M | -39.4M | 18.2M | -41.3M | -14.5M | 1.7M | -1.3M | -11.2M | -16.9M | -39.3M | -33.9M | -24M | -15.1M | -19M | 29.8M | -23.5M | -20.2M | -2.2M | |
50.4M | 129.4M | 140M | 264.5M | 312.4M | 203.8M | 373.7M | 199.7M | 114.5M | 116.4M | 94.5M | 79.5M | 53.3M | 58.7M | 104.3M | 105.6M | 143.2M | 72.6M | 47M | 71.7M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -104.4M | -66.9M | -47.1M | -48M | -63.9M | -134.5M | -77.7M | -43.5M | -47.3M | -33.4M | -42.4M | -47.9M | -69M | -38.4M | -37.1M | -27.6M | -13.4M | -22.6M | -11.5M | |
(0.0) | -277.8M | (0.0) | -27.5M | -113.4M | (3.7M) | -30.5M | (26.7M) | -1.2B | (225K) | -328.9M | -320.9M | -3M | -7.3M | -152M | -5.2M | -60.8M | -86.9M | -100.8M | -228.7M | |
(0.0) | -49M | -32.7M | -4.9M | (0.0) | -7.8M | -207M | (0.0) | (293K) | (0.0) | -4.1M | (0.0) | (0.0) | -67.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -13.1M | |
0.0 | 54.5M | 5.4M | 4.9M | 76K | -3.7M | 1.6M | 0.0 | 17M | 0.0 | 0.0 | 0.0 | 0.0 | 64.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 109.9M | |
-108.1M | -14.1M | 0.0 | 16.1M | -55K | 3.7M | 65.7M | 1.3M | 483K | 4.5M | -9.7M | -4.1M | 535K | -10.2M | 0.0 | 0.0 | -2.3M | 411K | 411K | 689K | |
-108.1M | -390.8M | -94.2M | -58.6M | -161.4M | -68.1M | -304.7M | -49.7M | -1.2B | -42.6M | -372M | -363.3M | -50.3M | -79.3M | -190.4M | -42.3M | -88.4M | -100.3M | -123M | -142.7M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
736K | -52.5M | -275M | -125M | 0.0 | -100M | 0.0 | 349.6M | -7.1M | 0.0 | 219.7M | 15.2M | 152.5M | 0.0 | -83.5M | -31.3M | 0.0 | 11.5M | -66.1M | -54.2M | |
46.7M | 299.4M | 54.5M | -107.8M | -100M | 305.5M | -9.2M | -488.8M | 1.2B | -16.2M | 76.1M | 229.4M | -135M | 7.8M | 161.6M | 16.8M | -178M | 140.4M | 230M | 98.5M | |
-221K | -52.5M | -275M | -125M | (0.0) | -100M | -6.5M | (0.0) | -7.1M | -4.9M | (0.0) | (0.0) | (0.0) | (0.0) | -83.5M | -31.3M | (0.0) | (0.0) | -106.5M | -70M | |
-19.1M | -9M | -9.4M | -24.6M | 1.8M | -78.8M | 434K | -41.7M | -13.9M | 1.1M | 172M | -1.8M | 1.6M | 4.3M | -18M | 12.9M | 6.7M | 1.6M | -55.4M | 1.3M | |
28.3M | 237.9M | -229.9M | -252M | -98.2M | 121.6M | 64.5M | -180.9M | 1.2B | -15.1M | 258.5M | 242.8M | 19M | 12.1M | 60.1M | -1.6M | -171.3M | 153.5M | 108.5M | 45.6M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
18M | -6.5M | 3.9M | -10.7M | -9.5M | 13.9M | -4.2M | -5M | 10.7M | -4.7M | -4.8M | -7.6M | 1.7M | 4.6M | -2M | -4.8M | 4.8M | 356K | 2.1M | 1.2M | |
-11.3M | -30M | -180.3M | -56.8M | 43.3M | 271.3M | 60.1M | -36.1M | 72.9M | 53.9M | -23.9M | -48.6M | 23.7M | -3.9M | -28M | 56.9M | -111.7M | 126.2M | 34.6M | -24.2M | |
246.4M | 276.4M | 456.7M | 513.4M | 470.2M | 198.9M | 138.8M | 174.9M | 102.1M | 48.1M | 72M | 120.6M | 96.9M | 100.8M | 128.8M | 71.9M | 183.5M | 57.3M | 22.7M | 46.9M | |
235M | 246.4M | 276.4M | 456.7M | 513.4M | 470.2M | 198.9M | 138.8M | 174.9M | 102.1M | 48.1M | 72M | 120.6M | 96.9M | 100.8M | 128.8M | 71.9M | 183.5M | 57.3M | 22.7M | |
-31.1M | 25M | 73.1M | 217.4M | 264.3M | 139.9M | 239.2M | 121.9M | 71M | 69.1M | 61.1M | 37.1M | 5.4M | -10.3M | 65.9M | 68.4M | 115.7M | 59.2M | 24.5M | 60.2M |
IART - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 08, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 06, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 30, 2025 | September 30, 2025 | 2025 |
Continue your IART research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.